Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
CGON Stock Chart & Stats
$58.80
-$0.55(-1.77%)
At close: 4:00 PM EST
$58.80
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$14.80 - $60.00
Previous Close$30.46
Volume740.02K
Average Volume (3M)922.89K
Market Cap
$4.74B
Enterprise Value$4.72B
Total Cash (Recent Filing)$742.15M
Total Debt (Recent Filing)$7.02M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
May 07, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding80,666,176
10 Day Avg. Volume696,597
30 Day Avg. Volume922,887
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.17K
Enterprise Value/Gross Profit-7.77K
Enterprise Value/Ebitda-28.20
Forecast
1Y Price Target
$82.60Price Target Upside40.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.65
Revenue Forecast (FY)$21.74M
Bulls Say, Bears Say
Bulls Say
Clinical Trial Enrollment And ReadoutRapid enrollment in the pivotal randomized registrational trial accelerates the expected topline readout and increases visibility into efficacy and potential label expansion into intermediate‑risk disease.
Market Expansion PotentialAnalyst highlights that approval in the intermediate‑risk non‑muscle invasive bladder cancer setting could unlock a large, less-contested commercial opportunity and position the therapy as a preferred backbone for urology centers.
Regulatory PathwayAnalyst notes biologics license application progress and Breakthrough and Fast Track designations could enable an accelerated approval pathway, shortening regulatory review and improving prospects for market entry.
Bears Say
Durability And Guideline AdoptionAnalyst warns uncertain long-term durability and unclear ability to prevent cystectomy could restrict guideline adoption and limit uptake in community treatment settings.
Financial Runway And Market RiskAnalyst flags elevated cash burn and notable short interest as factors that may create financing pressure and amplify downside risk if clinical or commercial progress slows.
Manufacturing And Regulatory Submission RiskInvestors cite manufacturing readiness concerns tied to the regulatory submission, with unresolved issues potentially delaying approval or creating supply constraints at launch.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $14.80 and its highest was $60.00 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $4.74B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is May 07, 2026 which is in 65 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Feb 27, 2026. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.6 by $0.05.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.57.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 80,666,176 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.6. Following the earnings report the stock price went up 4.794%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.60 (40.48% Upside)
$82.60 (40.48% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 44.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.63%
12-Months-Change
Fundamentals
Return on Equity
-21.67%
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CGON Stock 12 Month Forecast
Average Price Target
$82.60
▲(40.48% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
10.61% Insiders
23.87% Mutual Funds
15.11% Other Institutional Investors
35.71% Public Companies and
Individual Investors